Central Precocious Puberty Clinical Trial
Official title:
Patient Characteristics, Treatment Patterns, and Resource Usage in Children Diagnosed With Central Precocious Puberty (CPP) in China
The main purpose is to describe how many children were treated during 24 months or less because of CPP and how treatment worked for them. There are no participants in this trial, the study only involves reviewing participants medical past and current records and collecting information.
This is an observational, non-interventional, retrospective study to evaluate the participants characteristics, current treatment patterns and resource usage in Chinese pediatric participants diagnosed with CPP. This study will enroll approximately 400 participants. The data available in an existing data source the Chinese CPP Big Data Platform database will be analyzed. All the participants will be assigned to a single observational cohort: • Pediatric Participants With CPP This multi-center trial will be conducted in China. The overall duration of the study will be approximately 18 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02920515 -
Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty
|
Phase 4 | |
| Completed |
NCT00779103 -
Histrelin Subcutaneous Implant in Children With Central Precocious Puberty
|
Phase 3 | |
| Completed |
NCT04736602 -
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.
|
Phase 3 | |
| Recruiting |
NCT05341115 -
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
|
Phase 4 | |
| Completed |
NCT02993926 -
A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
|
||
| Recruiting |
NCT02811471 -
Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
|
Phase 3 | |
| Completed |
NCT03316482 -
Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty
|
Phase 4 | |
| Recruiting |
NCT06129539 -
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty
|
Phase 3 | |
| Completed |
NCT01634321 -
The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty
|
Phase 4 | |
| Terminated |
NCT02006680 -
Markers of Pubertal Suppression During Therapy for Precocious Puberty
|
||
| Completed |
NCT01278290 -
Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls
|
Phase 3 | |
| Completed |
NCT02427958 -
A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
|
Phase 4 | |
| Completed |
NCT05029622 -
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
|
Phase 3 | |
| Recruiting |
NCT06025409 -
Evaluate the Efficacy and Safety of DWJ108J
|
Phase 3 | |
| Completed |
NCT01467882 -
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
|
Phase 3 | |
| Recruiting |
NCT00438217 -
Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children
|
Phase 4 |